Timeliness of routine childhood vaccination among 12-35 months old children in The Gambia: Analysis of national immunisation survey data, 2019-2020.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Vaccination* ; Immunization*; Infant, Newborn ; Humans ; Child ; Infant ; Child, Preschool ; Gambia/epidemiology ; Immunization Schedule ; Immunization Programs ; Hepatitis B Vaccines

The Gambia's routine childhood vaccination programme is highly successful, however, many vaccinations are delayed, with potential implications for disease outbreaks. We adopted a multi-dimensional approach to determine the timeliness of vaccination (i.e., timely, early, delayed, and untimely interval vaccination). We utilised data for 3,248 children from The Gambia 2019-2020 Demographic and Health Survey. Nine tracer vaccines administered at birth and at two, three, four, and nine months of life were included. Timeliness was defined according to the recommended national vaccination windows and reported as both categorical and continuous variables. Routine coverage was high (above 90%), but also a high rate of untimely vaccination. First-dose pentavalent vaccine (PENTA1) and oral polio vaccine (OPV1) had the highest timely coverage that ranged from 71.8% (95% CI = 68.7-74.8%) to 74.4% (95% CI = 71.7-77.1%). Delayed vaccination was the commonest dimension of untimely vaccination and ranged from 17.5% (95% CI = 14.5-20.4%) to 91.1% (95% CI = 88.9-93.4%), with median delays ranging from 11 days (IQR = 5, 19.5 days) to 28 days (IQR = 11, 57 days) across all vaccines. The birth-dose of Hepatitis B vaccine had the highest delay and this was more common in the 24-35 months age group (91.1% [95% CI = 88.9-93.4%], median delays = 17 days [IQR = 10, 28 days]) compared to the 12-23 months age-group (84.9% [95% CI = 81.9-87.9%], median delays = 16 days [IQR = 9, 26 days]). Early vaccination was the least common and ranged from 4.9% (95% CI = 3.2-6.7%) to 10.7% (95% CI = 8.3-13.1%) for all vaccines. The Gambia's childhood immunization system requires urgent implementation of effective strategies to reduce untimely vaccination in order to optimize its quality, even though it already has impressive coverage rates.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Wariri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Vaccine. 2017 Dec 18;35(51):7166-7173. (PMID: 29132992)
PLoS One. 2021 Oct 21;16(10):e0258961. (PMID: 34673828)
PLoS Med. 2013;10(5):e1001404. (PMID: 23667334)
Stat Med. 2021 Apr;40(9):2197-2211. (PMID: 33540473)
JAMA. 1991 Sep 18;266(11):1547-52. (PMID: 1880887)
PLoS One. 2014 Sep 18;9(9):e107280. (PMID: 25232830)
Lancet. 2009 May 2;373(9674):1543-9. (PMID: 19303633)
Wkly Epidemiol Rec. 2009 Dec 18;84(50):533-40. (PMID: 20034143)
PLoS One. 2021 Feb 26;16(2):e0247415. (PMID: 33635913)
PLoS Med. 2012;9(10):e1001330. (PMID: 23109915)
Epidemiol Infect. 2012 Sep;140(9):1599-606. (PMID: 22074684)
Vaccine. 2021 Apr 28;39(18):2584-2594. (PMID: 33824039)
Vaccine. 2018 Mar 14;36(12):1583-1591. (PMID: 29454519)
Nat Med. 2005 Apr;11(4 Suppl):S5-11. (PMID: 15812490)
Lancet. 1988 Oct 8;2(8615):811-4. (PMID: 2902264)
PLoS One. 2011 Feb 28;6(2):e17155. (PMID: 21386886)
Vaccine. 2016 Jun 17;34(29):3335-41. (PMID: 27195759)
Lancet Glob Health. 2021 Mar;9(3):e280-e290. (PMID: 33607028)
Hepatology. 2004 Jan;39(1):211-9. (PMID: 14752840)
BMC Public Health. 2018 Dec 11;18(1):1364. (PMID: 30537969)
Lancet Infect Dis. 2019 Nov;19(11):1246-1254. (PMID: 31548081)
Hum Vaccin Immunother. 2019;15(3):740-747. (PMID: 30457475)
Vaccine. 2022 May 9;40(21):2925-2932. (PMID: 35422336)
Vaccine. 2001 Feb 28;19(15-16):1951-9. (PMID: 11228365)
BMJ Glob Health. 2019 Sep 06;4(5):e001713. (PMID: 31565416)
Vaccine. 2019 Jan 29;37(5):732-741. (PMID: 30579756)
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S420-S428. (PMID: 34590128)
BMC Health Serv Res. 2015 Aug 28;15:346. (PMID: 26315547)
PLOS Glob Public Health. 2022 Jul 14;2(7):e0000325. (PMID: 36962319)
Paediatr Drugs. 2007;9(3):143-8. (PMID: 17523694)
Lancet. 2008 Apr 12;371(9620):1247-58. (PMID: 18406859)

MC_UU_00026/2 United Kingdom MRC_ Medical Research Council; MC_UU_00026/3 United Kingdom MRC_ Medical Research Council; MC_UU_00031/3 United Kingdom MRC_ Medical Research Council; MR/R010161/1 United Kingdom MRC_ Medical Research Council

0 (Hepatitis B Vaccines)

Date Created: 20230721 Date Completed: 20231023 Latest Revision: 20240320

20240320

PMC10361478

10.1371/journal.pone.0288741

37478124